Identification of cancer stem cells is crucial for advancing cancer biology and therapy. Several markers including CD24, CD44, CD117, CD133, the G subfamily of ATP-binding cassette transporters (ABCG), epithelial specific antigen (ESA) and aldehyde dehydrogenase (ALDH) are used to identify and investigate human epithelial cancer stem cells in the literature. We have now systemically analyzed and compared the expression of these markers in fresh ovarian epithelial carcinomas. Although the expression levels of these markers were unexpectedly variable and partially overlapping in fresh ovarian cancer cells from different donors, we reliably detected important levels of CD133 and ALDH in the majority of fresh ovarian cancer. Furthermore, most of these stem cell markers including CD133 and ALDH were gradually lost following in vitro passage of primary tumor cells. However, the expression of ALDH and CD133, but not CD24, CD44 and CD117, could be partially rescued by the in vitro serum-free and sphere cultures and by the in vivo passage in the immune-deficient xenografts. ALDH 1 and CD133 1 cells formed three-dimensional spheres more efficiently than their negative counterparts. These sphere-forming cells expressed high levels of stem cell core gene transcripts and could be expanded and form additional spheres in long-term culture. ALDH 
1 cells are enriched with ovarian cancer-initiating (stem) cells and that ALDH and CD133 may be widely used as reliable markers to investigate ovarian cancer stem cell biology.
Ovarian carcinoma is a deadly disease characterized by late diagnosis, early metastasis and resistance to therapy. Although the majority of patients initially respond to platinum-based chemotherapy, most will subsequently succumb to chemoresistant, recurrent disease. Long-term treatment success is limited by the development of chemoresistant disease. This may be partially due to the immunosuppressive networks formed in the human ovarian cancer microenvironment. In the last several years, our research team has focused on the human ovarian carcinoma microenvironment and has demonstrated that immune cells in human ovarian carcinoma have been reprogrammed by active tumor-mediated processes to defeat tumor immunity and in turn temper the clinical efficacy of chemotherapy. [1] [2] [3] [4] It is also possible that existing therapies primarily target the bulk of the ovarian carcinoma cell population rather than the cancer-initiating cells (or stem cells or stem-like cells). [5] [6] [7] [8] [9] [10] [11] Although multiple markers including CD44, CD117, 12 CD133 13,14 and Hoechst positive ''side population'' 15 are used to identify ovarian cancer stem cells, the concept of ovarian cancer stem cells remains controversial, and the nature of these ovarian cancer stem cells has not been well defined in fresh ovarian cancer and primary tumor cells. Aldehyde dehydrogenase (ALDH) has been used to investigate multiple human cancer stem cells. [16] [17] [18] [19] [20] [21] [22] Recent reports showed that ALDH þ ovarian cancer cells possess stem cell properties. 23, 24 However, it is not well understood if ovarian cancer stem cells universally express ALDH, CD133 and other markers and if ALDH expression is phenotypically and functionally associated to many other reported markers for ovarian cancer stem cells. In our study, we revisited this issue and examined fresh ovarian cancer tissues, primary ovarian cancer cells and xenografted ovarian cancer cells in our laboratory and focused our studies on identifying and comparing potential ovarian cancer stem cells and the regulatory effects of in vitro and in vivo environments on the property of ovarian cancer stem cells.
Material and Methods

Human subjects
We studied previously untreated patients with epithelial ovarian carcinomas (n ¼ 25). The patients gave written informed consent. Our study was approved by the University of Michigan.
Cells and tissues
Cells and tissues were obtained from ascites and tumors as described. [25] [26] [27] Fresh tumors were processed into single cell suspension as described and immediately used for enrichment or flow analysis. [25] [26] [27] Potential cancer stem cells were enriched by depleting CD45-PE positive immune cells, including macrophages, myeloid dendritic cells, plasmacytoid dendritic cells, B and T cell subsets (PE-selection kit; StemCell Technologies, Vancouver, Canada) and sorted with FACSAria (Becton Dickinson, San Jose, CA) as we previously described. [25] [26] [27] Dead cells were excluded. Cell purity was >98% as confirmed by flow cytometry (LSR II, Becton Dickinson, San Jose, CA). Primary ovarian cancer cells were established from fresh ascites or/and tumor tissues. Tumor cells were initially enriched with double Ficoll separation with 100% Ficoll-Metrizoate (1.077 g/ml) on the bottom, followed by a layer of 75% Ficoll-Metrizoate on the top (1.057 g/ml). Tumor cells were enriched on the top layer. Other cells were on the middle layer, and the debris containing erythrocytes and polynuclear cells was on the lower layer. The enriched tumor cells were further sorted with high-speed sorter (FACSAria, Becton Dickinson, San Jose, CA). The cells were either cultured under conventional condition [10% fetal calf serum (FCS), RPMI medium, all from GIBCO, Invitrogen, Carlsbad, CA] as a monolayer or serum-free (X-vivo20; Lonza, Basel, Switzerland) and sphere culture conditions (nonadherent, X-vivo20; Lonza, Basel, Switzerland).
Flow cytometry analysis
Cells were stained with specific antibodies against human CD3, CD4, CD8, CD11b, CD11c, CD14, CD19, CD24, CD44, CD117, CD133, Annexin V (BD Biosciences, San Diego, CA) and ESA (StemCell Technologies, Vancouver, Canada). Samples were acquired on a LSR II, and data were analyzed with DIVA software (BD, Biosciences, San Diego, CA). The ALDEFLUOR (ALDH) kit (StemCell Technologies, Vancouver, Canada) was used to identify and sort ALDH þ cells with high ALDH enzymatic activity by FACSAria as described. 16, 17 Briefly, single cells were suspended in ALDH assay buffer containing ALDH substrate-BAAA (BODIPY-aminoacetaldehyde) and incubated at 37 C for 40 min. In each experiment, the specific ALDH inhibitor diethylaminobenzaldehyde was used as negative control at 50 mmol/l. Other cells including CD133 þ and ABCG2 þ were sorted based on the surface antigen expression.
Immunofluorescence analysis
Immunofluorescence analysis was performed as described. 27, 28 Tissues were stained with monoclonal mouse anti-human-CD133 (1/100 dilution; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) followed by Alexa Fluor 568-conjugated goat anti-mouse IgG (2 lg/ml; Molecular Probes, Invitrogen, Carlsbad, CA) and with Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human ESA (1/100 dilution; StemCell Technologies, Vancouver, Canada). Positive cells were quantified by ImagePro Plus software (Media Cybernetics, Inc., Silver Spring, MD) and expressed as the mean of the percent positive cells 6 standard deviation in 10 high-powered fields using confocal microscopy.
Sphere formation
The sphere assay was performed as described. 16, 17 Briefly, tumor cells or electronically sorted tumor cell subsets were plated in ultralow attachment plates (Corning, One Riverfront Plaza, NY) in serum-free EBM-2 or X-VIVO medium (Lonza, Basel, Switzerland) supplemented with 5 lg/ml insulin (Sigma-Aldrich, St. Louis, MO) and 20 ng/ml human recombinant epidermal growth factor (Invitrogen, Carlsbad, CA), at a density of 1,000-10,000 viable cells/well. Spheres (>50 lm) were counted for 1-6 weeks.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated with Qiagen Reagent (Qiagen, Valencia, CA). The RNA was reverse transcribed into cDNA using oligo-dT primers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The primer sequence combinations spanned contact sequences of subsequent exons. For amplification, the SyberGreen qPCR mix was used (Invitrogen, Carlsbad, CA). Each reaction was run in triplicate on the Mastercycler machine (Eppendorf, Hamburg, Germany) and was normalized to housekeeping gene GAPDH transcripts.
In vivo tumor formation
Ovarian tumor cell subsets (10 2 -5 Â 10 6 ) in 100 ll of buffered saline were subcutaneously injected into dorsal tissues of female NOD/Shi-scid/IL-2Rcnull [nitric oxide dismutatesevere combined immunodeficiency IL-2 receptor c null mice (NSG)] mice (6-8 weeks old; Jackson Laboratory, Bar Harbor, ME), similar to our studies in NOD.SCID mice. 28, 29 Tumor size was measured twice weekly using calipers fitted with a Vernier scale. Tumor volume was calculated based on three perpendicular measurements. 28, 29 Cancer Cell Biology 
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Statistical analysis
Differences in cell surface molecule expression were determined by v 2 test, and the differences in other variables were determined by Mann-Whitney test, with p < 0.05 being considered significant.
Results
Expression of multiple potential cancer stem cell markers in fresh ovarian tumors CD24, CD44, CD117, CD133, ABCG2 and ESA are used to define cancer stem cells in multiple human epithelial cancers [30] [31] [32] including ovarian cancer. [12] [13] [14] Recently, ALDH was also applied for identifying cancer stem cells. [7] [8] [9] 19, 20, [30] [31] [32] [33] We initially examined the expression of these markers in fresh ovarian tumor cells. To this end, ovarian tumors were excised, and single cell suspensions were made. and other nonepithelial cells (ESA À ) were gated out for stem cell marker analysis (Fig. 1a) . Multicolor flow cytometry analysis revealed a significant lin
population in fresh ovarian cancer tissues (Fig. 1a) . This population was also observed in the fresh ascites fluid in patients with ovarian cancer (not shown). We reasoned that the potential ovarian cancer stem cells could be included in lin Original dot plots showed the relationship between ALDH and ABCG2 (n ¼ 12).
Cancer Cell Biology ESA þ in fresh ovarian cancer tissues (Figs. 1d and 1e ). As the expression levels of cancer stem cell markers were considerably variable from patient to patient, we showed the levels of cancer stem cell marker expression in individual patients (Fig. 1b) (Table 1) . In six individual patients, we found that the rate of tumor formation was reliably higher in mice received different numbers of ALDH þ cells (Fig. 3a) , CD133 þ cells (Fig. 3b) and Fig. 3c ; (Table 2) . When
ulations were further isolated from the newly formed xenografted tumors and inoculated into NSG mice, similar tumorforming capacity was observed (Fig. 3c, not þ cells were more efficient in sphere formation than their negative counterparts (Fig. 4c) . We next examined if the sphere cells could be expanded and kept sphere-forming capacity. The sphere cells were harvested and subjected to further sphere culture. As expected, the sphere cells were able to form and expand spheres in culture for more than 2 months (Fig. 4d) . Furthermore, although it was mechanistically 
þ ALDH þ and their negative counterparts were sorted from fresh human ovarian cancer and injected into NSG mice as described in Figures 1a and 1b . The rate of tumor formation (%) was shown in mice that received different numbers of tumor cell subpopulations. The observation time is up to 48 days.
unknown, we noticed that the morphological appearance of the spheres was different from one donor to another (Fig.  4d) . We quantified and compared selected stem cell core genes in sphere cells and conventional cultured primary parental tumor cells. Real-time The polymerase chain reaction (PCR) revealed that the levels of SOX2, OCT3/4 and NANOG were higher in sphere cells than parental cells (Fig.  4e) . ALDH þ and CD133 þ cells were enriched in the sphere cells (Figs. 4b and 4c) . Altogether, these data suggest that ALDH þ and CD133 þ cells are capable of self-renewal in vitro (Fig. 4 ) and in vivo ( 
þ ALDH þ cells were isolated and sorted from tumors formed in the NSG mice and were injected into new NSG mice as described in Figs. 1a and 1b . The percentage of CD133 þ and ALDH þ cells was analyzed in the total tumor population from NSG mice from two patients. The observation time is up to 48 days.
Cancer stem cell markers in fresh cancer cells, primary cancer cells and xenograft tumors
Majority of previous investigators have used established or/ and commercialized ovarian cancer cell lines to conduct cancer stem cell research. Our research team has established multiple primary cancer cell lines from patients with ovarian cancer. We examined and compared cancer stem cell markers in fresh tumor cells, primary ovarian cancer cell lines and tumor cells cultured in vitro in different conditions and in tumor cells isolated from xenograft tumors. We observed that fresh OC18 cells contained a significant CD133 þ population (Fig. 5a ). However, following the conventional culture with 10% FCS, the proportion of cells expressing CD133 gradually decreased from 4-5% (Fig. 5a, upper panel) of the total population to 0-0.2% (Fig. 5a , lower panel) after 6 weeks in culture. Similar loss was observed for ALDH expression (not 
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Kryczek et al. shown). The loss of CD133 expression was universally observed in all primary ovarian cancer cell lines we established. Furthermore, after more than 6-8 weeks in conventional culture, the expression of CD24, CD44, CD117 and ABCG2 was either largely reduced or lost completely as compared to fresh ovarian cancer cells (Fig. 5a) . We next investigated whether the lost stem cell markers could be recovered in the in vivo xenograft passages or in vitro serum-free culture. We inoculated the in vitro cultured primary tumor cells (Fig. 5a) into NSG mice. These cells formed tumors in vivo. The tumor cells were subsequently isolated from the NSG mice for multiple stem cell marker analysis (Figs. 5b-5d) . We found that xenograft-derived tumors expressed appreciable levels of ALDH (Fig. 5b, upper  panel) , CD133 and ABCG2 (Fig. 5b, lower panel) , but negligible levels of CD44 and CD117 (Fig. 5b, lower panel) . When the xenograft-derived tumor cells were further cultured under conventional condition with 10% FCS, the expression of ALDH (Fig. 5c, left panel) , CD133 (Fig. 5c , right panel) and ABCG2 (not shown) was gradually disappeared. When the primary tumor cells (Fig. 5d, upper panel) and xenograftderived tumor cells (Fig. 5d, lower panel) were in vitro cultured in serum-free conditions, the expression of CD133 was partially and rapidly recovered (Fig. 5d) . Similar results were obtained for ALDH expression. However, serum-free and sphere culture did not rescue (or induce) the expression of CD24, CD44, ABCG2 and CD117. Altogether, the data indicate that serum-free conditions and in vivo tumor transplantation are able to rescue (or induce) the expression of CD133 and ALDH, but not CD44 and CD117.
Discussion
In this study, we have examined and compared the expression of multiple cancer stem cell markers in fresh ovarian cancer and established primary ovarian cancer cell lines and investigated the stem cell properties of potential ovarian cancer stem cells in vitro and in vivo.
We have shown that although the levels of ALDH and CD133 expression are variable, expression is detectable in the majority of fresh ovarian tumors. Consistent with the cancer stem cell concept, ALDH þ and CD133 þ cells are able to efficiently form spheres and heterogeneous tumors in vivo with limited numbers of cells. ALDH is thought to be a marker for defining stem cells in multiple human epithelial cancers including breast cancer, 16, 21 colon cancer, 19, 20 hepatocellular carcinoma, 18 head and neck squamous cell carcinoma 22 and ovarian cancer. 23, 24 On the basis of these reports and current criteria including in vivo tumor formation with limited cells and sphere formation, we suggest that ALDH þ and CD133 þ cells may be enriched with cancer stem cells in the majority of human ovarian cancer. Although ALDH and CD133 can be used to identify ovarian cancer stem cells in fresh ovarian tumors, the expression of CD133, ALDH and other markers is gradually reduced following prolonged in vitro cell passages. In support of our observation, it has been demonstrated that tumor cells grown under standard serum-containing cell culture conditions result in the loss of tumor stem cells. 34 The loss of stem cell markers in vitro culture system suggests that the stem cell phenotype or/and properties may possibly need to be supported in vivo in the tumor microenvironment and that the in vitro conventional culture conditions may not be appropriate for maintaining the cancer stem cell phenotype. In support of this possibility, the expression of cancer stem cell markers CD133 and ALDH is partially recovered in the in vivo formed xenograft tumors and in the in vitro serum-free culture. Our results also indicate that the loss of stem cell markers may be reversible. However, it is unknown whether the recovered CD133 36 Interestingly, once the cells are exposed to conventional culture conditions, the expression of CD133 and ALDH rescued (or induced) by the serum-free culture conditions or the in vivo tumor passages gets lost again. Nonetheless, given that the expression of CD133 and ALDH appears within 12 hr in the in vitro serum-free culture and that the appearance of their expression is dependent on the environmental conditions, we speculate that genetic mutations may not be the major cause of driving CD133 and ALDH induction in our experimental conditions. This does not contradict with the notion that the combination of multiple genetic changes or/instability is of fundamental importance in tumorigenesis. Furthermore, fresh and induced CD133-and ALDH-expressing cells express high levels of stem cell core genes and efficiently form spheres and in vivo tumors. Altogether, the data support the conclusion that CD133-and ALDH-expressing cells are enriched with cancer stem cells and that these cells are important tools for studying ovarian cancer stem cell biology.
In addition to ALDH and CD133, other markers may be used in ovarian cancer stem cell research. ESA is expressed in fresh epithelial ovarian tumor cells. The expression of CD24 and CD44 is highly expressed in many fresh ovarian tumor cells we examined. ABCG2 þ and ABCG2 À ovarian cancer cells are equally tumorigenic. It has been reported that CD44 þ and CD117 þ can be used to identify ovarian cancer stem cells. 12, 37 Our data show that the expression of CD117 is not detectable in more than 50% of fresh ovarian tumors and in 100% primary ovarian cancer cells established in 10% FCS conventional culture. Furthermore, the loss of CD44 and CD117 expression cannot be rescued by in vivo xenograft Cancer Cell Biology Kryczek et al. tumor passage and in vitro sphere culture. Based on these results, our data suggest that CD133 and ALDH can more accurately identify ovarian cancer stem cells and can be broadly used for ovarian cancer stem cell research in the majority of ovarian cancer. However, given the high heterogeneity of ovarian cancer types, it is important to note that CD44, CD117 and other markers could be used to investigate cancer stem cells in certain ovarian cancer types. Additionally, we have shown that CD133 À and ALDH À cells could be tumorigenic in vivo. It also indicates that CD133 and ALDH are not exclusive markers for ovarian cancer stem cells. The majority of published reports on human ovarian cancer stem cells used commercially available established ovarian cancer cell lines (or the unsorted tumors) or ''the cells'' isolated from the in vitro formed spheres or the mouse xenografts. [12] [13] [14] [15] 37 Macrophages, fibroblasts and many other cells express some stem cell markers including CD44 and CD24. As these cells are substantial populations in the tumor mass and may promote tumorigenesis, it is important to absolutely avoid their contamination in the ovarian cancer stem cell compartments. To this end, on the basis of our multicolor flow cytometry analysis, we have excluded all the possible nonepithelial cell fractions, including the immune cells (e.g., macrophages, T cells, and B cells), fibroblasts, vascular endothelial cells and CD34 þ progenitors and hematopoietic cells in our studies. We systemically compared multiple stem cell markers and directly sorted these cells from fresh human ovarian tumors and investigated their stemness properties, including self-renewal and in vivo tumorigenesis. Given that long-term culture may alter cancer stem cell properties, we have minimized the potential impact of long-term in vitro culture and the experimental manipulation on the properties of ovarian cancer stem cells. One of the key issues in cancer stem cell studies is the regulation of cancer stem cell self-renewal and expansion. These properties are not autonomous to stem cells, and recent evidence points to a level of external control from the microenvironment that defines the stem cell niche. 38, 39 This may explain why tumor stem cell markers are lost in the in vitro culture and are partially rescued in the in vivo model. Recent studies demonstrate that IL-6 40, 41 and IL-8 42 promote cancer stem cell-mediated tumorigenesis in vivo. We suggest that cancer stem cells may renew and expand in the tumor environment in vivo. The next step is to further define the tumor environmental factors and molecular signaling pathway crucial for regulating ovarian cancer stem cell properties.
We conclude that ALDH and CD133 are useful and reliable markers for investigating human ovarian cancer stem cells in the majority of patients with ovarian cancer. Our data indicate that the expression levels of multiple stem cell markers gradually diminish following prolonged culture in vitro. Therefore, fresh tumor cells are needed to investigate cancer stem cell biology.
